The Japanese pharmaceutical company Daiichi Sankyo has become a “Golden Ticket” sponsor of the BioM incubator MAxL (Munich Accelerator Life Sciences & Medicine) in Munich, Germany. Through this partnership, Daiichi Sankyo specifically supports emerging biotech start-ups thereby making an important contribution to promoting innovative therapeutic approaches in the biomedical field.

The incubator, based at the biotech hub of Munich-Martinsried and managed by the Bavarian cluster development organization BioM, is specifically designed to support pre-seed and early-stage start-up teams in the life sciences and healthtech sectors. It is intended to facilitate the translation of scientific findings into market-ready products thereby filling an important gap in the start-up ecosystem.

MAxL's Golden Ticket program enables an outstanding founding team to advance its research work in the incubator's state-of-the-art laboratory and co-working space free of charge for one year. The team also benefits from a tailored mentoring and networking program - including valuable contact with investors. Daiichi Sankyo has been actively involved in the selection process of the applicant teams and offers the winning start-up direct insights into the industry as well as access to its global network of experts and industry contacts.

Source: BioM